AMA Continental Listing and the SAHPRA reliance pathway
A positive continental opinion is not permission to sell. It is the scientific basis a national authority relies on to issue its own authorisation. Knowing where that line sits, and what SAHPRA now requires, is the difference between a 90 working day decision and a lost cycle.
Two stages, two different legal effects
Continental evaluation
The Evaluation of Medicinal Products Technical Committee assesses quality, safety and efficacy. The GMP Technical Committee assesses the manufacturing sites.
Positive opinion and listing
If standards are met, an independent scientific opinion is issued and the product is included in the Continental List. Assessment reports and the Summary of Product Characteristics are made available to national authorities.
National application
You still file nationally, with local Module 1 elements, fees, and any bridging data for local conditions. The authority verifies that the product is the same as the one assessed.
National authorisation
The authority performs any residual local benefit-risk assessment, may impose national conditions, and issues the marketing authorisation under its own law.
What SAHPRA's procedure actually requires
In February 2026 SAHPRA issued its Continental Listing procedure. Four rules decide whether an application is accepted or wasted.
Positive opinion first
An application may be submitted only after a positive AMA opinion has been issued. Not before.
The opinion letter travels with it
The AMA opinion letter must accompany the SAHPRA application.
No parallel submissions
Filing to SAHPRA while the continental process is still running is not accepted. This is the most expensive mistake available on this pathway.
The dossier must reflect the opinion
Any recommendations or conditions in the AMA opinion have to be carried into the dossier you file. SAHPRA aims to decide within 90 working days after screening.
What the listing does not do for you
- It does not give automatic authorisation in any other country.
- It does not waive national fees, local labelling or local pharmacovigilance obligations.
- It does not automatically cover variations, renewals or lifecycle changes, which remain largely national.
- It does not override national pricing, reimbursement or procurement rules.
- It does not remove the need to demonstrate and document sameness across every filing.
The residual work is where the risk sits: bridging data for climate zone and local epidemiology, sameness documentation, and commercial agreements that allocate risk if an authority imposes extra conditions or misses the expected timeline.
Common questions
Does a Continental Listing authorise me to sell?
No. It is a scientific opinion. Each national authority still issues its own marketing authorisation under its own law, using that opinion as the primary scientific basis.
Can I file with SAHPRA in parallel with the continental process?
No. Parallel submissions are not accepted. The application may only follow a positive AMA opinion, and the opinion letter must accompany it.
How long does SAHPRA take under this pathway?
SAHPRA aims to finalise within 90 working days after screening, assuming the dossier reflects the conditions in the AMA opinion and sameness is properly demonstrated.
Is my product eligible?
The continental procedure prioritises defined categories including new chemical entities, complex generics, vaccines and biologics, products for priority diseases, orphans and emergency-use products. Eligibility is confirmed per product.
This page describes the pathway as at 4 August 2026. Regulatory procedures, eligibility criteria and timelines change. Applicability to a specific product is confirmed against the current published procedures as part of an engagement, and nothing on this page is regulatory or legal advice.